References
- Pascale RM, Calvisi DF, Simile MM, et al. The Warburg effect 97 years after its discovery. Cancers (Basel). 2020;12(10):1. DOI:https://doi.org/10.3390/cancers12102819.
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.
- Vander Heiden MG, DeBerardinis RJ. Understanding the intersections between metabolism and cancer biology. Cell. 2017;168(4):657–669.
- Ge T, Yang J, Zhou S, et al. The role of the pentose phosphate pathway in diabetes and cancer. Front Endocrinol (Lausanne). 2020;11:365.
- Riganti C, Gazzano E, Polimeni M, et al. The pentose phosphate pathway: an antioxidant defense and a crossroad in tumor cell fate. Free Radic Biol Med. 2012;53(3):421–436. DOI:https://doi.org/10.1016/j.freeradbiomed.2012.05.006.
- Patra KC, Hay N. The pentose phosphate pathway and cancer.Trends Biochem Sci. 2014 [july 15];39(8):347–354. DOI:https://doi.org/10.1016/j.tibs.2014.06.005.
- Langbein S, Zerilli M, Zur Hausen A, et al. Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted. Br J Cancer. 2006;94(4):578–585. DOI:https://doi.org/10.1038/sj.bjc.6602962.
- Cho ES, Cha YH, Kim HS, et al. The Pentose Phosphate Pathway as a Potential Target for Cancer Therapy. Biomol Ther (Seoul). 2018;26(1):29–38. DOI:https://doi.org/10.4062/biomolther.2017.179.
- Weber G. Biochemical strategy of cancer cells and the design of chemotherapy: G H A Clowes Memorial Lecture. Cancer Res. 1983;43:3466–3492.
- Jin L, Zhou Y. Crucial role of the pentose phosphate pathway in malignant tumors (review). Oncol Lett. 2019;17(5):4213–4221.
- Guo, Tan, Chen, et al. Targeting cancer metabolism to resensitize chemotherapy: potential development of cancer chemosensitizers from traditional Chinese medicines. Cancers (Basel). 2020;12(2):404. DOI:https://doi.org/10.3390/cancers12020404.
- Giacomini I, Ragazzi E, Pasut G, et al. The pentose phosphate pathway and its involvement in cisplatin resistance. Int J Mol Sci. 2020;Jan 31;21(3):937.
- Mitsuishi Y, Taguchi K, Kawatani Y, et al. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell. 2012;22(1):66–79. DOI:https://doi.org/10.1016/j.ccr.2012.05.016.
- Zhang Q, Yi X, Yang Z, et al. Overexpression of G6PD represents a potential prognostic factor in clear cell renal cell carcinoma. J Cancer. 2017;8(4):665–673. DOI:https://doi.org/10.7150/jca.16858.
- Zhang Q, Han Q, Yang Z, et al. G6PD facilitates clear cell renal cell carcinoma invasion by enhancing MMP2 expression through ROS‑MAPK axis pathway. Int J Oncol. 2020 april 8[];57(1):197–212. DOI:https://doi.org/10.3892/ijo.2020.5041.
- Chan B, VanderLaan PA, Sukhatme VP. 6-Phosphogluconate dehydrogenase regulates tumor cell migration in vitro by regulating receptor tyrosine kinase c-Met. Biochem Biophys Res Commun. 2013;439(2):247–251.
- Chou Y-T, Jiang J-K, Yang M-H, et al. Identification of a noncanonical function for ribose-5-phosphate isomerase A promotes colorectal cancer formation by stabilizing and activating β-catenin via a novel C-terminal domain. . PLOS Biol. 2018;Jan 16;16(1):e2003714.
- Ciou S-C, Chou Y-T, Liu Y-L, et al., Ribose-5-phosphate isomerase A regulates hepatocarcinogenesis via PP2A and ERK signaling. Int J Cancer. 2015;137(1): 104–115. . https://doi.org/10.1002/ijc.29361.
- Li M, Zhang X, Lu Y, et al. The nuclear translocation of transketolase inhibits the farnesoid receptor expression by promoting the binding of HDAC3 to FXR promoter in hepatocellular carcinoma cell lines. Cell Death Dis. 2020;11(1):31. DOI:https://doi.org/10.1038/s41419-020-2225-6.
- Chao Y-K, Peng T-L, Chuang W-Y, et al. Transketolase serves a poor prognosticator in esophageal cancer by promoting cell invasion via epithelial-mesenchymal transition. J Cancer. 2016;7(13):1804–1811. DOI:https://doi.org/10.7150/jca.15467.
- Pes GM, Errigo A, Soro S, et al. Glucose-6-phosphate dehydrogenase deficiency reduces susceptibility to cancer of endodermal origin. Acta Oncol. 2019;58(9):1205–1211. DOI:https://doi.org/10.1080/0284186X.2019.1616815.
- Choi J, Kim E-S, Koo JS. Expression of pentose phosphate pathway-related proteins in breast cancer. Dis Markers. 2018;2018:9369358.
- Mele L, la Noce M, Paino F, et al. Glucose-6-phosphate dehydrogenase blockade potentiates tyrosine kinase inhibitor effect on breast cancer cells through autophagy perturbation. J Exp Clin Cancer Res. 2019;38(1):160. DOI:https://doi.org/10.1186/s13046-019-1164-5.
- Benito A, Polat IH, Noé V, et al. Glucose-6-phosphate dehydrogenase and transketolase modulate breast cancer cell metabolic reprogramming and correlate with poor patient outcome. Oncotarget. 2017;8(63):106693–106706. DOI:https://doi.org/10.18632/oncotarget.21601.
- Wang C, Guo K, Gao D, et al. Identification of transaldolase as a novel serum biomarker for hepatocellular carcinoma metastasis using xenografted mouse model and clinic samples. Cancer Lett. 2011;313(2):154–166. DOI:https://doi.org/10.1016/j.canlet.2011.08.031.
- Heinrich PC, Morris HP, Weber G. Behavior of transaldolase (EC 2.2.1.2) and transketolase (EC 2.2.1.1) activities in normal, neoplastic, differentiating, and regenerating liver. Cancer Res. 1976;36(9 pt.1):3189–3197.
- Silvers CR, Miyamoto H, Messing EM, et al. Characterization of urinary extracellular vesicle proteins in muscle-invasive bladder cancer. Oncotarget. 2017;8(53):91199–91208. DOI:https://doi.org/10.18632/oncotarget.20043.
- Hanczko R, Fernandez DR, Doherty E, et al. Prevention of hepatocarcinogenesis and increased susceptibility to Acetaminophen-induced liver failure in transaldolase-deficient mice by N-acetylcysteine. J Clin Invest. 2009;119(6):1546–1557. DOI:https://doi.org/10.1172/JCI35722.
- Ahopelto K, Saukkonen K, Hagström J, et al. TKTL1 as a prognostic marker in pancreatic ductal adenocarcinoma and its correlation with FDG-PET-CT. Oncology. 2020;99:1–9.
- da Costa IA, Hennenlotter J, Stühler V, et al. Transketolase like 1 (TKTL1) expression alterations in prostate cancer tumorigenesis. Urol Oncol Semin Orig Investig. 2018;36:472.e21–472.e27.
- Qin Z, Xiang C, Zhong F, et al., Transketolase (TKT) activity and nuclear localization promote hepatocellular carcinoma in a metabolic and a non-metabolic manner. J Exp Clin Cancer Res. 2019;38(1): 154. https://doi.org/10.1186/s13046-019-1131-1.
- Xu IM-J, Lai RK-H, Lin S-H, et al. Transketolase counteracts oxidative stress to drive cancer development. Proc Natl Acad Sci U S A. 2016 [january 25];113(6):E725–E734. DOI:https://doi.org/10.1073/pnas.1508779113.
- Ricciardelli C, Lokman NA, Cheruvu S, et al. Transketolase is upregulated in metastatic peritoneal implants and promotes ovarian cancer cell proliferation. Clin Exp Metastasis. 2015;32(5):441–455. DOI:https://doi.org/10.1007/s10585-015-9718-1.
- Zhao M, Ye M, Zhou J, et al. Prognostic values of transketolase family genes in ovarian cancer. Oncol Lett. 2019 [september 6];18(5):4845–4857. DOI:https://doi.org/10.3892/ol.2019.10818.
- Tao L, Yu H, Liang R, et al. Rev-erbα inhibits proliferation by reducing glycolytic flux and pentose phosphate pathway in human gastric cancer cells. Oncogenesis. 2019;8(10):57. DOI:https://doi.org/10.1038/s41389-019-0168-5.
- Tian G, Li G, Liu P, et al. Glycolysis-based genes associated with the clinical outcome of pancreatic ductal adenocarcinoma identified by the cancer genome atlas data analysis. DNA Cell Biol. 2020;39(3):417–427. DOI:https://doi.org/10.1089/dna.2019.5089.
- Schwaab J, Horisberger K, Ströbel P, et al. Expression of Transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy. BMC Cancer. 2011;11(1):363. DOI:https://doi.org/10.1186/1471-2407-11-363.
- Diaz-Moralli S, Tarrado-Castellarnau M, Alenda C, et al. Transketolase-like 1 expression is modulated during colorectal cancer progression and metastasis formation. PLoS One. 2011;6(9):e25323.
- Peltonen R, Ahopelto K, Hagström J, et al. High TKTL1 expression as a sign of poor prognosis in colorectal cancer with synchronous rather than metachronous liver metastases. Cancer Biol Ther. 2020;21(9):826–831. DOI:https://doi.org/10.1080/15384047.2020.1803008.
- Song Y, Liu D, He G. TKTL1 and p63 are biomarkers for the poor prognosis of gastric cancer patients. Cancer Biomarkers. 2015;15(5):591–597.
- Chen X, Xu Z, Zhu Z, et al. Modulation of G6PD affects bladder cancer via ROS accumulation and the AKT pathway in vitro. Int J Oncol. 2018;53(4):1703–1712. DOI:https://doi.org/10.3892/ijo.2018.4501.
- Chen L, Zhang Z, Hoshino A, et al. NADPH production by the oxidative pentose-phosphate pathway supports folate metabolism. Nat Metab. 2019;1(3):404–415. march 11. https://doi.org/10.1038/s42255-019-0043-x. .
- Yang H-C, Y-h W, Yen W-C, et al. The redox role of G6PD in cell growth, cell death, and cancer. Cells. 2019;8(9):1055. DOI:https://doi.org/10.3390/cells8091055.
- Perillo B, Di Donato M, Pezone A, et al. ROS in cancer therapy: the bright side of the moon. Exp Mol Med. 2020;52(2):192–203. DOI:https://doi.org/10.1038/s12276-020-0384-2.
- Hu T, Zhang C, Tang Q, et al. Variant G6PD levels promote tumor cell proliferation or apoptosis via the STAT3/5 pathway in the human melanoma xenograft mouse model. BMC Cancer. 2013;13(1):251. DOI:https://doi.org/10.1186/1471-2407-13-251.
- Mele L, Paino F, Papaccio F, et al. A new inhibitor of glucose-6-phosphate dehydrogenase blocks pentose phosphate pathway and suppresses malignant proliferation and metastasis in vivo. Cell Death Dis. 2018;9(5):572. DOI:https://doi.org/10.1038/s41419-018-0635-5.
- Raı̈s B, Comin B, Puigjaner J, et al. Oxythiamine and dehydroepiandrosterone induce a G 1 phase cycle arrest in Ehrlich’s tumor cells through inhibition of the pentose cycle. FEBS Lett. 1999;456(1):113–118. DOI:https://doi.org/10.1016/S0014-5793(99)00924-2.
- Preuss J, Richardson AD, Pinkerton A, et al. Identification and characterization of novel human glucose-6-phosphate dehydrogenase inhibitors. J Biomol Screen. 2013;18(3):286–297. DOI:https://doi.org/10.1177/1087057112462131.
- He C, Yang J, Ding J, et al. Downregulation of glucose‑6‑phosphate dehydrogenase by microRNA‑1 inhibits the growth of pituitary tumor cells. Oncol Rep. 2018;40(6):3533–3542. DOI:https://doi.org/10.3892/or.2018.6755.
- Gao X, Zhao L, Liu S, et al. γ-6-phosphogluconolactone, a byproduct of the oxidative pentose phosphate pathway, contributes to AMPK activation through inhibition of PP2A. Mol Cell. 2019;76(6):857–871.e9. october 2. https://doi.org/10.1016/j.molcel.2019.09.007. .
- Ghergurovich JM, Esposito M, Chen Z, et al., Glucose-6-phosphate dehydrogenase is not essential for K-Ras–driven tumor growth or metastasis. Cancer Res. 2020;80(18): 3820–3829. . https://doi.org/10.1158/0008-5472.CAN-19-2486.
- Ma H, Zhang F, Zhou L, et al., c-Src facilitates tumorigenesis by phosphorylating and activating G6PD. Oncogene. 2021;40(14): 2567–2580. https://doi.org/10.1038/s41388-021-01673-0 .
- Chen J, Cao S, Situ B, et al. Metabolic reprogramming-based characterization of circulating tumor cells in prostate cancer. J Exp Clin Cancer Res. 2018;37(1):127. DOI:https://doi.org/10.1186/s13046-018-0789-0.
- Fang Z, Jiang C, Feng Y, et al. Effects of G6PD activity inhibition on the viability, ROS generation and mechanical properties of cervical cancer cells. Biochim Biophys Acta Mol Cell Res. 2016;1863(9):2245–2254. DOI:https://doi.org/10.1016/j.bbamcr.2016.05.016.
- Lu M, Lu L, Dong Q, et al. Elevated G6PD expression contributes to migration and invasion of hepatocellular carcinoma cells by inducing epithelial-mesenchymal transition. Acta Biochim Biophys Sin (Shanghai). 2018;50(4):370–380. DOI:https://doi.org/10.1093/abbs/gmy009.
- Sukhatme VP, Chan B. Glycolytic cancer cells lacking 6-phosphogluconate dehydrogenase metabolize glucose to induce senescence. FEBS Lett. 2012;586(16):2389–2395.
- Polat IH, Tarrado-Castellarnau M, Bharat R, et al. Oxidative pentose phosphate pathway enzyme 6-phosphogluconate dehydrogenase plays a key role in breast cancer metabolism. Biology (Basel). 2021;10(2):85. DOI:https://doi.org/10.3390/biology10020085.
- Buj R, Chen C-W, Dahl ES, et al. Suppression of p16 Induces mTORC1-mediated nucleotide metabolic reprogramming. Cell Rep. 2019;28(8):1971–1980.e8. DOI:https://doi.org/10.1016/j.celrep.2019.07.084.
- Guo J, Zhang Q, Su Y, et al. Arginine methylation of ribose-5-phosphate isomerase A senses glucose to promote human colorectal cancer cell survival. Sci China Life Sci. 2020;63(9):1394–1405. DOI:https://doi.org/10.1007/s11427-019-1562-y.
- Qiu Z, Guo W, Wang Q, et al. MicroRNA-124 reduces the pentose phosphate pathway and proliferation by targeting PRPS1 and RPIA mRNAs in human colorectal cancer cells. Gastroenterology. 2015;149(6):1587–1598.e11. DOI:https://doi.org/10.1053/j.gastro.2015.07.050.
- Mariadasse R, Biswal J, Jayaprakash P, et al. Mechanical insights of oxythiamine compound as potent inhibitor for human transketolase-like protein 1 (TKTL1 protein). J Recept Signal Transduct. 2016;36(3):233–242. DOI:https://doi.org/10.3109/10799893.2015.1080272.
- Cao L, Hong W, Cai P, et al. Cryptotanshinone strengthens the effect of gefitinib against non-small cell lung cancer through inhibiting transketolase. Eur J Pharmacol. 2021;890:173647.
- Lu H, Zhu H. Effect of siRNA-mediated gene silencing of transketolase on A549 lung cancer cells.Oncol Lett. 2017 [september 8];14(5):5906–5912. DOI:https://doi.org/10.3892/ol.2017.6916.
- Yang C-M, Liu Y-Z, Liao J-W, et al. The in vitro and in vivo anti-metastatic efficacy of oxythiamine and the possible mechanisms of action. Clin Exp Metastasis. 2010;27(5):341–349. DOI:https://doi.org/10.1007/s10585-010-9331-2.
- Xu X, Zur Hausen A, Coy JF, et al. Transketolase-like protein 1 (TKTL1) is required for rapid cell growth and full viability of human tumor cells. international Journal of Cancer. 2009;124(6):1330–1337. DOI:https://doi.org/10.1002/ijc.24078.
- Diaz-Moralli S, Aguilar E, Marin S, et al. A key role for transketolase-like 1 in tumor metabolic reprogramming. Oncotarget. 2016;7(32):51875–51897. DOI:https://doi.org/10.18632/oncotarget.10429.
- Li J, Zhu S-C, Li S-G, et al. TKTL1 promotes cell proliferation and metastasis in esophageal squamous cell carcinoma. Biomed Pharmacother. 2015;74:71–76.
- Lin R, Elf S, Shan C, et al., 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1–AMPK signalling. Nat Cell Biol. 2015;17(11): 1484–1496. https://doi.org/10.1038/ncb3255. .
- Yang X, Peng X, Huang J. Inhibiting 6-phosphogluconate dehydrogenase selectively targets breast cancer through AMPK activation. Clin Transl Oncol. 2018;20(9):1145–1152.
- Guo H, Xiang Z, Zhang Y, et al. Inhibiting 6-phosphogluconate dehydrogenase enhances chemotherapy efficacy in cervical cancer via AMPK-independent inhibition of RhoA and Rac1. Clin Transl Oncol. 2019;21(4):404–411. DOI:https://doi.org/10.1007/s12094-018-1937-x.
- Chen H, Wu D, Bao L, et al. 6PGD inhibition sensitizes hepatocellular carcinoma to chemotherapy via AMPK activation and metabolic reprogramming. Biomed Pharmacother. 2019;111:1353–1358.
- Endo H, Owada S, Inagaki Y, et al. Glucose starvation induces LKB1-AMPK-mediated MMP-9 expression in cancer cells. Sci Rep. 2018;8(1):10122. DOI:https://doi.org/10.1038/s41598-018-28074-w.
- Cao J, Sun X, Zhang X, et al. 6PGD upregulation is associated with chemo- and immuno-resistance of renal cell carcinoma via AMPK signaling-dependent NADPH-mediated metabolic reprograming. Am J Med Sci. 2020;360(3):279–286. DOI:https://doi.org/10.1016/j.amjms.2020.06.014.
- Momcilovic M, Shackelford DB. Targeting LKB1 in cancer – exposing and exploiting vulnerabilities. Br J Cancer. 2015;113(4):574–584.
- Vara-Ciruelos D, Dandapani M, Hardie DG. AMP-activated protein kinase: friend or Foe in cancer? Annu Rev Cancer Biol. 2020;4(1):1–16.
- Pollak N, Niere M, Ziegler M. NAD kinase levels control the NADPH concentration in human cells. J Biol Chem. 2007;282(46):33562–33571.
- Amjad S, Nisar S, Bhat AA, et al. Role of NAD+ in regulating cellular and metabolic signaling pathways. Mol Metab Internet]. 2021;49:101195. https://www.sciencedirect.com/science/article/pii/S2212877821000351
- Xiao W, Loscalzo J. Metabolic responses to reductive stress. Antioxid Redox Signal. 2020;32(18):1330–1347.
- Xiao W, Wang R-S, Handy DE, et al. NAD(H) and NADP(H) redox couples and cellular energy metabolism. Antioxid Redox Signal. 2018;28(3):251–272. DOI:https://doi.org/10.1089/ars.2017.7216.
- Bradshaw PC. Cytoplasmic and mitochondrial NADPH-coupled redox systems in the regulation of aging. Nutr. 2019 Feb 27;11(3):504.
- Altman BJ, Stine ZE, Dang CV. From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer. 2016;16(11):749.
- Pramono AA, Rather GM, Herman H, et al. NAD- and NADPH-contributing enzymes as therapeutic targets in cancer: an overview. Biomol. 2020;10(3):358. DOI:https://doi.org/10.3390/biom10030358.
- Ju H-Q, Lin J-F, Tian T, et al. NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications. Signal Transduct Target Ther. 2020;5(1):231. DOI:https://doi.org/10.1038/s41392-020-00326-0.
- van der Wilt CL, Backus HHJ, Smid K, et al. Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors. Cancer Res. 2001;61:3675–3681 .
- Tseng C-W, Kuo W-H, Chan S-H, et al., Transketolase regulates the metabolic switch to control breast cancer cell metastasis via the α-ketoglutarate signaling pathway. Cancer Res. 2018;78(11): 2799–2812 .https://doi.org/10.1158/0008-5472.CAN-17-2906. .
- Sun W, Liu Y, Glazer CA, et al. TKTL1 is activated by promoter hypomethylation and contributes to head and neck squamous cell carcinoma carcinogenesis through increased aerobic glycolysis and HIF1alpha stabilization. Clin Cancer Res. 2010;16(3):857–866. January 26. https://doi.org/10.1158/1078-0432.CCR-09-2604. .
- El Hassouni B, Granchi C, Vallés-Martí A, et al. The dichotomous role of the glycolytic metabolism pathway in cancer metastasis: interplay with the complex tumor microenvironment and novel therapeutic strategies. Semin Cancer Biol. 2020;60:238–248.
- Oronsky B, Scicinski J, Reid T, et al. RRx-001, a novel clinical-stage chemosensitizer, radiosensitizer, and immunosensitizer, inhibits glucose 6-phosphate dehydrogenase in human tumor cells. Discov Med. 2016;21(116):251–265.
- Perry CM, Figgitt DP. Zoledronic Acid. Drugs. 2004;64(11):1197–1211.
- Wang X, WU G, G CAO, et al. Zoledronic acid inhibits the pentose phosphate pathway through attenuating the Ras-TAp73-G6PD axis in bladder cancer cells. Mol Med Rep. 2015;12(3):4620–4625. DOI:https://doi.org/10.3892/mmr.2015.3995.
- Wang J, Zhang X, Ma D, et al. Inhibition of transketolase by oxythiamine altered dynamics of protein signals in pancreatic cancer cells. Exp Hematol Oncol. 2013;2(1):18. DOI:https://doi.org/10.1186/2162-3619-2-18.
- EpicentRx I.2016. RRx-001 in second line treatment of advanced cholangiocarcinoma prior to readministration of first-line therapy (EPIC). [Internet]. Clinicaltrials.gov. [cited 2021 Apr 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT02452970?id=NCT02452970&draw=2&rank=1&load=cart
- Yin X, Tang B, J-H L, et al. ID1 promotes hepatocellular carcinoma proliferation and confers chemoresistance to oxaliplatin by activating pentose phosphate pathway. J Exp Clin Cancer Res. 2017;36(1):166. DOI:https://doi.org/10.1186/s13046-017-0637-7.
- Lucarelli G, Galleggiante V, Rutigliano M, et al. Metabolomic profile of glycolysis and the pentose phosphate pathway identifies the central role of glucose-6-phosphate dehydrogenase in clear cell-renal cell carcinoma. Oncotarget. 2015;6(15):13371–13386. DOI:https://doi.org/10.18632/oncotarget.3823.
- Hong W, Cai P, Xu C, et al. Inhibition of glucose-6-phosphate dehydrogenase reverses cisplatin resistance in lung cancer cells via the redox system. Front Pharmacol. 2018;9:43.
- Catanzaro D, Gaude E, Orso G, et al., Inhibition of glucose-6-phosphate dehydrogenase sensitizes cisplatin-resistant cells to death. Oncotarget. 2015;6(30): 30102–30114. https://doi.org/10.18632/oncotarget.4945. .
- Catanzaro D, Nicolosi S, Cocetta V, et al. Cisplatin liposome and 6-amino nicotinamide combination to overcome drug resistance in ovarian cancer cells. Oncotarget. 2018;9(24):16847–16860. DOI:https://doi.org/10.18632/oncotarget.24708.
- Kleih M, Böpple K, Dong M, et al. Direct impact of cisplatin on mitochondria induces ROS production that dictates cell fate of ovarian cancer cells. Cell Death Dis. 2019;10(11):851. DOI:https://doi.org/10.1038/s41419-019-2081-4.
- Budihardjo II, Walker DL, Svingen PA, et al. 6-Aminonicotinamide sensitizes human tumor cell lines to cisplatin. Clin Cancer Res. 1998;4(1):117–130.
- Zheng W, Feng Q, Liu J, et al. Inhibition of 6-phosphogluconate dehydrogenase reverses cisplatin resistance in ovarian and lung cancer. Front Pharmacol. 2017;8:421.
- Yang H, X-L W, K-H W, et al. MicroRNA-497 regulates cisplatin chemosensitivity of cervical cancer by targeting transketolase. Am J Cancer Res. 2016;6(11):2690–2699.
- Dong Y, Wang M. Knockdown of TKTL1 additively complements cisplatin-induced cytotoxicity in nasopharyngeal carcinoma cells by regulating the levels of NADPH and ribose-5-phosphate. Biomed Pharmacother. 2017;85:672–678.
- Zhou J, Kang Y, Chen L, et al. The drug-resistance mechanisms of five platinum-based antitumor agents. Front Pharmacol. 2020;11:343.
- Galluzzi L, Senovilla L, Vitale I, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31(15):1869–1883. DOI:https://doi.org/10.1038/onc.2011.384.
- Köhler E, Barrach H-J, Neubert D. Inhibition of NADP dependent oxidoreductases by the 6-aminonicotinamide analogue of NADP. FEBS Lett. 1970;6(3):225–228.
- Zuo J, Zhao M, Liu B, et al. TNF‑α‑mediated upregulation of SOD‑2 contributes to cell proliferation and cisplatin resistance in esophageal squamous cell carcinoma. Oncol Rep. 2019;42(4):1497–1506. DOI:https://doi.org/10.3892/or.2019.7252.
- Zhang R, Tao F, Ruan S, et al. The TGFβ1-FOXM1-HMGA1-TGFβ1 positive feedback loop increases the cisplatin resistance of non-small cell lung cancer by inducing G6PD expression. Am J Transl Res. 2019;11(11):6860–6876.
- Brozovic A, Ambriović-Ristov A, Osmak M. The relationship between cisplatin-induced reactive oxygen species, glutathione, and BCL-2 and resistance to cisplatin. Crit Rev Toxicol. 2010;40(4):347–359.
- Noordhuis P, Laan AC, van de Born K, et al. Coexisting molecular determinants of acquired oxaliplatin resistance in human colorectal and ovarian cancer cell lines. Int J Mol Sci. 2019 Jul 24;20(15):3619.
- Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22(47):7265–7279.
- Peters GJ, Avan A, Ruiz MG, et al. Predictive role of repair enzymes in the efficacy of Cisplatin combinations in pancreatic and lung cancer. Anticancer Res. 2014;34(1):435–442.
- Ramos-Montoya A, Lee W-NP, Bassilian S, et al., Pentose phosphate cycle oxidative and nonoxidative balance: a new vulnerable target for overcoming drug resistance in cancer. Int J Cancer. 2006;119(12): 2733–2741. https://doi.org/10.1002/ijc.22227. .
- Feng Q, Li X, Sun W, et al. Discovery of Ebselen as an inhibitor of 6PGD for suppressing tumor growth. Cancer Manag Res. 2020;12:6921–6934.
- Wang Z, Liang S, Lian X, et al. Identification of proteins responsible for Adriamycin resistance in breast cancer cells using proteomics analysis. Sci Rep. 2015;5(1):9301. DOI:https://doi.org/10.1038/srep09301.
- Goldman A, Khiste S, Freinkman E, et al. Targeting tumor phenotypic plasticity and metabolic remodeling in adaptive cross-drug tolerance. Sci Signal. 2019;12(595):eaas8779. DOI:https://doi.org/10.1126/scisignal.aas8779.
- Dong T, Kang X, Liu Z, et al. Altered glycometabolism affects both clinical features and prognosis of triple-negative and neoadjuvant chemotherapy-treated breast cancer. Tumor Biol. 2016;37(6):8159–8168. DOI:https://doi.org/10.1007/s13277-015-4729-8.
- Ma L, Cheng Q. Inhibiting 6-phosphogluconate dehydrogenase reverses doxorubicin resistance in anaplastic thyroid cancer via inhibiting NADPH-dependent metabolic reprogramming. Biochem Biophys Res Commun. 2018;498(4):912–917.
- Meredith A-M, Dass CR. Increasing role of the cancer chemotherapeutic doxorubicin in cellular metabolism. J Pharm Pharmacol. 2016;68(6):729–741.
- Gewirtz D. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics Adriamycin and daunorubicin. Biochem Pharmacol. 1999;57(7):727–741.
- Gorini S, De Angelis A, Berrino L, et al. Chemotherapeutic drugs and mitochondrial dysfunction: focus on doxorubicin, trastuzumab, and sunitinib. Oxid Med Cell Longev. 2018;2018:7582730.
- Chen M-B, X-y W, J-H G, et al. Activation of AMP-activated protein kinase contributes to doxorubicin-induced cell death and apoptosis in cultured myocardial H9c2 cells. Cell Biochem Biophys. 2011;60(3):311–322. DOI:https://doi.org/10.1007/s12013-011-9153-0.
- Polimeni M, Voena C, Kopecka J, et al. Modulation of doxorubicin resistance by the glucose-6-phosphate dehydrogenase activity. Biochem J. 2011;439(1):141–149. DOI:https://doi.org/10.1042/BJ20102016.
- Zhu Y, Xu J, Hu W, et al. TFAM depletion overcomes hepatocellular carcinoma resistance to doxorubicin and sorafenib through AMPK activation and mitochondrial dysfunction. Gene. 2020;753:144807.
- Feng Q, Li X, Sun W, et al. Targeting G6PD reverses paclitaxel resistance in ovarian cancer by suppressing GSTP1. Biochem Pharmacol. 2020;178:114092.
- Zheng X, Li H. TKTL1 modulates the response of paclitaxel-resistant human ovarian cancer cells to paclitaxel. Biochem Biophys Res Commun. 2018;503(2):572–579.
- Abal M, Andreu JM, Barasoain I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets. 2003;3(3):193–203.
- Alexandre J, Batteux F, Nicco C, et al. Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel-induced cancer cell death both in vitro and in vivo. Int J Cancer. 2006;119(1):41–48. DOI:https://doi.org/10.1002/ijc.21685.
- Sawers L, Ferguson MJ, Ihrig BR, et al. Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines. Br J Cancer. 2014;111(6):1150–1158. DOI:https://doi.org/10.1038/bjc.2014.386.
- Stolfi RL, Colofiore JR, Nord LD, et al. Biochemical modulation of tumor cell energy: regression of advanced spontaneous murine breast tumors with a 5-fluorouracil-containing drug combination. Cancer Res. 1992;52(15):4074–4081.
- Mahmood U, Street JC, Matei C, et al. In vivo detection by31P NMR of pentose phosphate pathway block secondary to biochemical modulation. NMR Biomed. 1996;9(3):114–120. DOI:https://doi.org/10.1002/(SICI)1099-1492(199605)9:3<114::AID-NBM413>3.0.CO;2-O.
- Jahani M, Azadbakht M, Norooznezhad F, et al. l -arginine alters the effect of 5-fluorouracil on breast cancer cells in favor of apoptosis. Biomed Pharmacother. 2017;88:114–123.
- Shukla SK, Purohit V, Mehla K, et al. MUC1 and HIF-1alpha signaling crosstalk induces anabolic glucose metabolism to impart gemcitabine resistance to pancreatic cancer. Cancer Cell. 2017;32(1):71–87.e7. DOI:https://doi.org/10.1016/j.ccell.2017.06.004.
- Samatiwat P, Prawan A, Senggunprai L, et al. Nrf2 inhibition sensitizes cholangiocarcinoma cells to cytotoxic and antiproliferative activities of chemotherapeutic agents. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2016;37(8):11495–11507. DOI:https://doi.org/10.1007/s13277-016-5015-0.
- Pinedo HM, Peters GF. Fluorouracil: biochemistry and pharmacology. J Clin Oncol Off J Am Soc Clin Oncol. 1988;6(10):1653–1664.
- Peters GJ, van der Wilt CL, van Groeningen CJ, et al. Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. J Clin Oncol Off J Am Soc Clin Oncol. 1994;12(10):2035–2042. DOI:https://doi.org/10.1200/JCO.1994.12.10.2035.
- Spears CP, Gustavsson BG, Berne M, et al. Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil. Cancer Res. 1988;48(20):5894–5900.
- Tattersall MH, Jackson RC, Connors TA, et al. Combination chemotherapy: the interaction of methotrexate and 5-fluorouracil. Eur J Cancer. 1973;9(10):733–739. DOI:https://doi.org/10.1016/0014-2964(73)90064-9.
- Peters GJ, Laurensse E, Leyva A, et al. The concentration of 5-phosphoribosyl 1-pyrophosphate in monolayer tumor cells and the effect of various pyrimidine antimetabolites. Int J Biochem. 1985;17(1):95–99. DOI:https://doi.org/10.1016/0020-711X(85)90091-6.
- Zhang Y, Chen M, Liu M, et al. Glycolysis-related genes serve as potential prognostic biomarkers in clear cell renal cell carcinoma. Oxid Med Cell Longev. 2021 Jan 23;2021:6699808.
- Park Beom J, Lee Sun J, Lee Sun M, et al. Corosolic acid reduces 5‑FU chemoresistance in human gastric cancer cells by activating AMPK. Mol Med Rep. 2018;18(3):2880–2888. DOI:https://doi.org/10.3892/mmr.2018.9244.
- Boros LG, Puigjaner J, Cascante M, et al. Oxythiamine and dehydroepiandrosterone inhibit the nonoxidative synthesis of ribose and tumor cell proliferation. Cancer Res. 1997;57(19):4242–4248.
- Liu C-L, Hsu Y-C, Lee -J-J, et al. Targeting the pentose phosphate pathway increases reactive oxygen species and induces apoptosis in thyroid cancer cells. Mol Cell Endocrinol. 2020;499:110595.
- Li L, Fath MA, Scarbrough PM, et al. Combined inhibition of glycolysis, the pentose cycle, and thioredoxin metabolism selectively increases cytotoxicity and oxidative stress in human breast and prostate cancer. Redox Biol. 2015;4:127–135.
- Yang W-H, Qiu Y, Stamatatos O, et al. Enhancing the efficacy of glutamine metabolism inhibitors in cancer therapy. Trends Cancer. 2021;7(8):790–804. DOI:https://doi.org/10.1016/j.trecan.2021.04.003.
- Endicott M, Jones M, Hull J. Amino acid metabolism as a therapeutic target in cancer: a review. Amino Acids. 2021;53(8):1169–1179.
- Ding Y, Gong C, Huang D, et al. Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers. Nat Commun. 2018;9(1):4274. DOI:https://doi.org/10.1038/s41467-018-06651-x.
- Hong X, Song R, Song H, et al. PTEN antagonises Tcl1/hnRNPK-mediated G6PD pre-mRNA splicing which contributes to hepatocarcinogenesis. Gut. 2014;63(10):1635–1647 . DOI:https://doi.org/10.1136/gutjnl-2013-305302.
- Ju HQ, Lu YX, Wu QN, et al. Disrupting G6PD-mediated Redox homeostasis enhances chemosensitivity in colorectal cancer. Oncogene. 2017 [july 10];36(45):6282–6292. DOI:https://doi.org/10.1038/onc.2017.227.
- Liu R, Li W, Tao B, et al. Tyrosine phosphorylation activates 6-phosphogluconate dehydrogenase and promotes tumor growth and radiation resistance. Nat Commun. 2019;10(1):991. DOI:https://doi.org/10.1038/s41467-019-08921-8.
- Ghergurovich JM, García-Cañaveras JC, Wang J, et al. A small molecule G6PD inhibitor reveals immune dependence on pentose phosphate pathway. Nat Chem Biol Internet]. 2020;16:731–739. Available from. ;(7):. : http://www.nature.com/articles/s41589-020-0533-x.
- Nagashio R, Oikawa S, Yanagita K, et al. Prognostic significance of G6PD expression and localization in lung adenocarcinoma. Biochim Biophys Acta - Proteins Proteomics. 2019;1867(1):38–46. DOI:https://doi.org/10.1016/j.bbapap.2018.05.005.